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Bovine a,-antiplasmin (a,AP) has been purified and partially charactorizcd. The amino acid composition is very similar to that of human azAP, 
and the N-terminal (23 residues determined) and reactive site loop sequences (42 rcsiducs determined) are highly homolog,ous tothose of the human 
pn ,:l:in. Compurcd with human asAP, bovine a:AP has an lb-residue N-terminal extension, homologous with part of the pre-sequence of human 
azAP. A re-investigation of the N-terminal sequence of freshly prepared human a,AP reveals a new form extended by 12 residues. 
Plasma protein; Proteinase inhibitor; Sequence analysis; a:-Antiplasmin 
1. INTRODUCTION 
The plasma protein, a2-antiplasmin (a,AP), is a mcm- 
ber of the serpin class of inhibitors [l-3]. Human azAP 
is a 70 kDa single-chain protein containing 14% carbo- 
hydrate [4] and two disulfide bridges. Mature a,AP con- 
sists of 452 residues [5], and pre-a,AP appears to con- 
tain a 39 [5] or 37-residue [6] signal sequence. The reac- 
tive site peptide bond (P,-P,‘) cleaved during complex 
formation with plasmin is Arg3M-Met [S]. A secondary 
site interacting with plasmin(ogen) is located in the C- 
terminal part of a2AP [7,8]. 
Bovine a2AP has not previously been characterized, 
and commercial polyclonal anti(human a,AP) antibod- 
ies do not react with bovine cr,AP. As part of a study 
of the components of the fibrinolytic system in bovine 
milk we have isolated bovine a,AP from plasma. As a 
first step in the characterization of bovine a,AP we 
report here its partial N-terminal sequence and 42 resi- 
dues of internal sequence, covering its reactive site, 
2. MATERIALS AND METHODS 
2. I, iwc&reriafs 
Porcine pancreatic lastase type IV and DC1 were obtained from 
Corrmpondence addwss: L. Sottrup-Jensen. Department ofMolecular 
Biology, University of Arhus, CF. Mollers Alle building 130, 8000 
Arhus C, Denmark. Fax: (45) 8619 6500. 
Abbreviutions: azAP. as-antiplasmin; serpin, serine protease inhibitor; 
DCI, 3,4-dichloroisocoumarin; CTA, committee of thrombolytic 
agents; E-ACA, &-aminocaproic a id; K, kringle region of p!asmino- 
gun; HPLC, high performance liquid chromatograph(y); TFA, tri- 
fluoroacctic acid. 
Sigma. Bovine chymoirypsin A was from Eoehringcr-Mannheim. 
Srrtpkylococc~rs m-em V8 protensc was from Worthington. Tosyl- 
phcnylalanine chloromethylketone-treated trypsin was from Cooper 
Biomedicals. Subtilisin was From Nova-Nordic. Urokinase from Ab- 
bott (30,000 CTA U/mg) was used for activation of p!asminogen. 
Bovine blood was obtained from a local slaughter house and anticoag- 
ulatcd with trisodium citrate. After separation of plasma by centrifu- 
gation it was stored at -20%. The substrate H-o-Pro-L-Phc-L-Arg-p- 
nitroanilide.2 HCI (S-2302) was from Kabi. 
2.2. Prqmarior~ o$ Iysitw-Sepkarose and KI.3-Sepharose 
Lysine-Sepharosc was prupared according to [9]. Bovine plasmino- 
gcn was purified from plasma as described 1101. 3 a of alasminogen 
dissolved- in 800 ml 0.i M NMdHCOx was biiested wiih 1.5% w/w 
clustasc and the fragments eparated essentially according to [I 11. 
Kl-3 (358 nao units) was coupled to I I g of CNBr-activated Sepha- 
rose according to the instructions from Pharmacia. 
2.3. Pw@crrtfon oJ’ bovitrc uttd huttlart alAP 
As in [ 121 and [ 131, plusminogen-depleted plasma was fractionated 
with (NH,)$!iO+ The proteins precipitating berwlsn 0.8 and 2.7 M 
were dissolved in 40 mM sodium phosphate, 2 mM EDTA, pH 7.4, 
(buffer A) and dialyzed against 100 vols. ofdcionizcd water to prccip- 
itate Fibrinogen. After ccntrifugation, the supcrnatant from 300 ml of 
plasma was made up to 40 mM in sodium phosphate, and 2 mM in 
EDTA, pH 7.4, and treated with 40 ml Kl-J-Sepharose equiiibrated 
with buffer A. The KI3-Scpharose was washed on a BLichncr funnel 
and poured into a column. Loosely bound proteins were eluted’with 
buffer A containing 0.5 M N&I, and a,AP was eluted by including 
20 mM E-ACA in the buffer. The presence of orzAP in the column 
fractions was monitored by observing an approx. 70 kDa band in 
reducing SDS-PAGE. IO-ml fractions containing a,AP were applied 
to a Superose 12 column (2.5 x 40 cm) equilibrated and eluted with 
buffer A containing 0.5 M NaCl and 20 mM s-ACA. Contnminating 
immunoglobulins were removed by passing the a,AP preparation 
through a 4 ml protein A-Sepharose column equilibrated and cluted 
with the same buffer. Human a2AP was purified by the same method 
as for bovine azAP except hat a plasminogen-Scpharose column (60 
mg plasminogen/ml Sepharose) was used instead of Kl-J-Sepharose. 
100 Publihd by Ehvier Science Publisfrers B. V. 
Volu~ne 312, number 1 FEBS LETTERS November I992 
Plasminogcn (4.4 mgIml in 0. I M sodium phosphate, pH 7.3) was 
activated by incubation with urokinase (0.8 CTA U/g8 plasminogen) 
for 2 h at room temperature. Fractions from Superosc 12 were dia- 
lysed against buffer A and analyzed ror E~AP activity by incubating 
50 ~1 samples with 50 ~1 plasmin (0.08 mg/ml in 0.1 M sodium phos- 
phate, pH 7.3) for 30 min at 25°C. After the addition of25OplO.2 mM 
S-2302 the change in absorbance at 405 nm WBS followed for 20 min. 
2.5. Preparariori qf clemed a,A P 
Reactive site cleaved a,AP was prepared by incubation with plasmin 
and subtilisin (ES = I:1 and 1:2,008 W/Y, respectively) for I min at 
25T. The enzyme was then inactivated by the addition of DCI. The 
C-terminal peptide was separated by SDS-PAGE [14,I5]. 
Hydrolyses were done at I 10DC in 6 M HCYl% thioglycolic acid for 
3. 16, 24 and 72 Ii. To determine the half-cysteine content, samples 
were oxidized with IO ,uI I M HCOOOH prior to hydrolysis, Free 
amino acids were separated by HPLC cation exchange using a pH 
gradient ranging from 3.10 to 10.10, as described [IG]. 
2.7. SDS-PAGE 
Protein purity and size estimation were performed ingels with linear 
gradients of acrylamide (IO-20%, 2.5% bis-acrylamide) [14]. 
2.8. N-Twrtrittuf ,seqmtce umdysis 
Proteins and fra8ments were transferred from the SDS-PAGE gels 
to ProBlou membranes using elcclroblouing [17]. Edmsn degrada- 
tions were done in an AD 477A sequenator equipped with a 120A 
on-line HPLC. The Donblot reaction and conversion cycles were used. 
Peptides were degraded on polybrene-coated glass-filters using the 
Normal- I cycles. Initial yields of N-terminal umino acids were 20-200 
pniol. 
Bovine-a,AP (280 pg) was dissolved in 200 ,!fi 0.25 M Tris-HCI, I 
mM EDTA. 6 M guanidine-1-Q pH 8.5, and reduced by the addition 
of IO ,uI 2-mercaptoethunol diluted I:10 in water and incubated at 
room tcmperaturc for 2 h. Then iodoacetdmide was added to 0.3 M. 
After reaction for 2 h at room tcnipcralure the alkylatcd &AP was 
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Fig. 1. SDS-PAGE of bovine IX~AP &ring purifir~tion. Lane !, size 
markers, reduced. Lane 2, pool elutd from Kl-3-Scpharose. Lane 3, 
aiter protein A-Scpharose chromatography. Lane 4, after Suprose 
12 gel chromalography. Lanes 2-4 are unreducrd. 
desalted on a Nucleosil C-4 TOO-7 column (4 x 125 mm). The protein 
was clutcd with a gradient of 0.1% TFA and acetonitrile and dried in 
a speed-vat centrifuge. The digestion was done in 0.2 M NH4HCOJ 
using 4% trypsin. After incubation for 5 h at 37OC the digest was 
lyophilizcd, dissolved in 0.1% TFA, and separated on a C-18 Nuclcvssil 
108-5 column (4 x 250 mm). The clution was performed at SOOC wilh 
a linear gradient ofacetonitrilc from 4.5% to 76.5% in 0.1% TFA over 
60 min at a flow rate 0r I ml/min. 
3. RESULTS AND DLSCUSSLON 
3.1. PuriJicurion of bovine cr,AP 
The purification of bovine a,AP was based on affinity 
chromatography on Kl-3-Scpharose as in [12,13]. 
However, when working with bovine plasma, contami- 
nating fibrinogen and immunoglobulin were present in 
large amounts. To prevent saturation of the Kl-P- 
Sepharose with fibrinogen, the major part of it was 
precipitated by dialysis before absorption. The a2AP 
pool from K134epharose was still contaminated with 
fibrinogen and immunoglobulin, but no tetranectin and 
histidine-rich glycoprotein could be detected (Fig. 1). 
However, in some preparations minor contaminants 
were present. A 28 kDa f:*otein was identiifted as a 
fragment of bovine apolipoprotein(a) by N-terminal se- 
quence analysis (DDPQSSXDRVK) and a 60 kDa pro- 
tein with the N-terminal sequence (FQRGQVLSAL- 
PRTSH) might represent bovine plasma carboxypepti- 
TaHe I 
Amino acid composition of bovine and human a,-antiplasmin 
Amino acid Bovine a2AP Human a,AP’ 
(mol %) (mol %) 
A5% IO.1 7.7 
Thr” 4.2 4.9 
SC+ 7.3 7.7 
Glx 13.2 13.7 
Pro 8.5 8.2 
GUY 5.3 5.8 
Ala 7.3 6.4 
CYS I .o 0.9 
Val” 4.6 6.2 
Met 2.5 2.2 
IIC” 2.3 2.0 
Leu 15.0 14.8 
Tyr I .4 0.9 
Phe 5.5 6.2 
His 2.4 2.7 
Lys 5.0 4.2 
Ar6 4.3 4.2 
Trp n.d. 1.3 
GalcN - tmc& 
GlcN’ 3.1 I .3’ 
“Values extrnpolatcd to 0 h. 
bValuc~ determined after 72 h of hydrolysis. 
‘CorrectuI for a loss of 25% during a 3 h hydrclysis pried. 
“Taken from the cDNA squcncc 161. 
CData from [4]. 
n.d., not determined. 
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Bovine a2AP FSPVSQMEPLDLQLHDGPAQEKL 
::::: :::: :: :: :: 
Human pre-apAP ma1lwg1lvlswsc~qgpcsvrspvsamoplgrqltsgpNQEQV~PLTLL~L~t~ 
Human azAP MEPLGXQLTSGPNQ 
Human a+P (2) NQEQVSPLTLLKL 
Fig, 2. Comparison of the N-terminal sequences or bovine and human azAP. Small letters arc used to indicalc the prc-sequence in human WQ 
(61, CWital ktters indicate the mitture sequence. X, not identified, Human 02AP( I) and human alAP(2), the two forms orqAP, are round in aPPrO%. 
cquimokir amounts. identical t&dues in bovine and buman &AP arc shown by a pair of dots; residues different in bovine a2AP are showI in 
bold. 
dase B [IS] (results not shown). The contaminating im- 
_munoglobttlin was removed by passage through a pro- 
tein A-Sepharose column. Residual fibrinogen was PC- 
moved by gel filtration on Superose 12 (Fig. I), About 
5 mg of bovine a,AP was obtained from 1 I of plasmin- 
ogen depleted plasma. 
The amino acid composition of bovine azAP was 
determined and compared with ehe human a2AP (Table 
I), The compositions of the two proteins agreed within 
f 10% except for Asx, Val and Tyr which differed more 
than 30%. Bovine z,AP contained N-acetyl-glucosam- 
ine, indicating the presence of N-linked carbohydrate as 
in human a,AP. The &IQ defined in [191 gives a value 
of about 12, indicating highly similar amino acid se- 
quences. However, although bovine and human e,AP 
have similar amino acid compositions no cross-reaciion 
is found using polyclonal antibodies (Dako, Copen- 
hag,en) to the human protein (datasheet from Dako, and 
unpublished). - 
In contrast to the Ala-13-Met site the Pro-I--Asn site 
of human pre-a?AP fits poorly to the “-3 to -1 rule” 
[21], and it might be questioned whether the latter se- 
A 6 
. . . 
0, - , kDa kDa 
- -180 
1 - -120 
me’?? - 90 
llsyldc - -60 
W? 43 - 
G -8.5 
N -6,5 
- 2.5 
1 2 1 2 
3.2. N-Temitzcrl seyuetzcc arzalysis of bovine alAP 
The sequence of the first 23 residues of bovine a,AP 
and its alignment with the sequence of human cc,AP are 
shown in Fig. 2. Relative To human a,AP, bovine a,AP 
has an l&residue extension which is clearly homolo- 
gous to part of the presumed 39.residue pre-sequence of 
human a,AP. Only one N-terminal requsnce (NQEQ) 
was reported earlier for human cr,AP [4]. However, se- 
quence analysis of a fresh preparation of human a,AP 
revealed that, besides this sequence, another sequence 
in approx. equimolar yield was present (Fig. 2). That 
sequence included the last 12 residues of the prese- 
quence of human cl,AP, These findings are in line wirh 
the recent observation that human pre-azAP cDNA ex- 
pressed in hamster kidney cc!!2 gives rig? to active a,AP 
containing that I2-residue xtension [20]. 
C 
kDa 
i,z ;;-,I 
w - 60 
- ‘: ‘,: - 43 
‘“lar iI:lL’: 
I_ 
Fig. 3. SDS-PAGE of cleaved preparations f bovine a,AP. (A) lane I, size markers; lane 2, CICOV~ bovine-a2AP preparation. (B) lane 1, Plasmin- 
bovine ~zAP complexes, plasmin (different forms), cleaved azAP and cleavage peptidc: lane 2, size markers. (C) Lane I subtilisin cleuvcd bovine 
a,AP and pcptidc; lane 2, size markers, Arrows indicate the C-terminal peptides resullinl: IloIn cle;ivWe. 
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C-O*APl 
C-azAP 
C-a2AP3 
T92 
TIBSPI 
TSSSF2 
HS-RMSLSSPIVNRF 
MSLS5FIVNRF 
SLS5FIVflRF 
LVVSSVQHQSALELSE3AGVQSl’A 
LVVSSVQHQSALE 
LSEAGVQMAATSTAHS-R 
Bovlna .+AP LVV6SVQHQSALELSEAGVQAAAAT5TAMS-RMSL9SFIVNRF 
:1:: :I*:: ::::: :: ::::*: ::: s:::::: :,:: 
Human ct2AP LWSGVCLIQETLELSEVGVEAAAATSIAMS-RMSLSSFSVNRP 
. . 
P and PI sitas is 10 5 ii, il ion 
Fig. 4. Reactive site sequence of bovine azAP. C-cz,AP’, C-02APz, 
C-azAP3, C-terminal peptidcs from a,AP cleaved wilb an clastase-like 
enzyme, plasmin and subtilisin, respec!isely. T52 and T55, see Fig. 5. 
T5SSPl and TSSSP2, peptidcs from S. UIWCUS V  proteinaso digcslion 
of T58. Bovine and human a,AP arc aligned according to [j] which 
introduces a gap between P, and P, in a,AP. Identical residues in 
bovine and buman azAP are sholvn by a pair of dots;residues different 
in bovine a,AP arc shown in bolrl. The P and P’ siles are numbcrcd. 
qucnce represents a site recognized by the processing 
enzyme. One possible explanation is that processing in- 
itially occurs at Ala -13-Met, and that the Pro-‘-Asn 
peptide bond is unstable and slowly cleaved by solvent. 
The change of the Ala-13-Met and Pro-‘-Asn sites in 
human a,AP to Gln-Met and Pro-Ala, respectively, in
bovine a,AP, is compatible with that protein having a 
single N-terminal extended by 18 residues when com- 
pared with buman alAP. 
3.3. Reactive site sequenncr 
Unlike human aSAP [13] the preparation of bovine 
ct2AF did not convert to forms of smaller size upon 
storage. However, one preparation was inactive, due to 
proteolysis in the reactive site loop as also seen with 
other serpins [2,,, 3 331. Sequence analysis of a 10 kDa 
peptide present in that preparation (Fig. 3) suggested 
that it resulted from cleavage of bovine CQAP by an 
elastase-like nzyme, that bovine a2AP had a similar 
reactive site (ArgW-Met), and that the 10 kDa peptide 
originated from cleavage 3residues upstream of this site 
(Fig. 4). Sequence analysis of the 10 kDa peptide gener- 
ated by incubation of bovine a,AP with bovine plasmin 
confirmed that the reactive site of bovine a,AP was 
identical to that of human aZAP. Sequence analysis of 
the peptide generated by incubation of bovine a,AP 
with subtilisin revealed that cleavage had occurred at 
the P,’ Met residue. 
To obtain sequence information covering the N-ter- 
minal part of the reactive site of bovine aZAP, tryptic 
peptides were analyzed (Fig. 5). Since the sequence anal- 
ysis had indicated high similarity of the reactive site 
sequences of bovine and human a,AP the amino acid 
composition of all HPLC fractions were determined. In 
human a,AP the corresponding tryptic peptide would 
be 37 residues long and contain 13% Ala residues. On 
the basis of a high content of Ala residues two 31- 
residue peptides, T52 and T58, were selected (Fig. 5). 
Except for the lower content of methionine in T52 their 
composition were identical. Sequence analysis of T52 
(28 residues determined) revealed a strong similarity 
with residues 373-414 of the reactive site loop of human 
aZAP (Fig. 4). By determining the sequences of peptides 
obtained from TSS by digestion with S. UUMUS V8 pro- 
teinase (T58SPl and 2, separation ot shown) the com- 
plete sequence OF a 42 residue segment of bovine a,AP 
containing its reactive site loop was established (Fig. 4). 
Among scrpins and other serine proteinase inhibitors 
the reactive site sequences of orthologous proteins how 
Fig. 5. HPLC chromatogram of tryptic pcptides from bovine a,AP. T52 and T58 wcrc used for sequence analysis. The IWO Met residues in T52 
wcrc probably oxidised to the sulfoxide form. 
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the greatest variation [24,25]. However, it is evident 
from the present work that for a,AP both the N-termi- 
nal sequences and the reactive site sequences of the 
bovine and human proteins are strongly conserved. 
A recent survey of serpin sequences [26] has pointed 
out the presence in functionally active inhibitors of a 
consensus sequence, Thr-Glu-Ala-Ala-Ala, correspond- 
ing to the P,,-P,, sites. This sequence is believed to be 
important for insertion of part of the reactive site loop 
into the extended A-sheet [3,26], thereby changing the 
loop from being a substrate to an inhibitor of pro- 
teinases. Of 20 proteins examined [3] only Cl-inhibitor, 
corticosteroid binding globulin and human a,AP have 
a Val-residue in P1+ With regard to P13, heparin cofac- 
tor I1 and angiotensinogen have a Gln residue in this 
position; however, neither corticosteroid binding globu- 
lin or angiotensinogen are active as inhibitors. Bovine 
azAP is a functionally active inhibitor, even though it 
contains two changes in the S-residue consensus e- 
quence (a Gin residue in P,3 and a Val residue in PI,). 
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